Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.77 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
PFE Q4 CY2025 Deep Dive: Obesity Pipeline and Cost Discipline Face Post-COVID Headwinds
Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue... 
Via StockStory
Topics Intellectual Property
News headline image
Will the Market Crash in 2026? Here's What History Says and What to Do About It ↗
Always be prepared. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unprofitable Stocks with Questionable Fundamentals
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Topics Electric Vehicles
News headline image
Pfizer Maps Post-Covid Reset With Obesity Trials And Deep Cost Cuts ↗
Via Talk Markets
Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling? ↗
Via Stocktwits
Pfizer Inc. (NYSE:PFE) Beats Q4 2025 Estimates but Muted Outlook Tempers Investor Reaction ↗
Via Chartmill
News headline image
Bristol-Myers Squibb Earnings: What To Look For From BMY
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what to expect. 
Via StockStory
News headline image
Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off ↗
The company expects to launch more than 20 pivotal late-stage trials this year. 
Via The Motley Fool
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗
Via Chartmill
Most active stocks in Tuesday's session ↗
Via Chartmill
News headline image
Pfizer (PFE) Q4 2025 Earnings Call Transcript ↗
Pfizer (PFE) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Pfizer Stock Dropped Today ↗
Is Pfizer stock a buy at under 9x earnings? Yes. It is. 
Via The Motley Fool
Topics Earnings
News headline image
Pfizer&#39;s Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops ↗
Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings that beat analyst estimates, signaling progress in its obesity pipeline. 
Via Benzinga
News headline image
Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update ↗
Pfizer stock tumbled early Tuesday after the drugmaker reaffirmed its modest outlook for 2026 and provided an obesity update. 
Via Investor's Business Daily
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025
Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue... 
Via StockStory
News headline image
Pfizer, Merck And 3 Stocks To Watch Heading Into Tuesday ↗
U.S. stock futures up, Pfizer, Teradyne, Merck & Co., Palantir, and AMD expected to release earnings reports. Palantir and AMD beat estimates. 
Via Benzinga
News headline image
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those... 
Via MarketMinute
Topics Economy Government Intellectual Property
News headline image
Is Novo Nordisk Stock a Bargain Right Now? ↗
Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs. 
Via The Motley Fool
News headline image
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims ↗
UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from Pfizer about Beyfortus promotion. 
Via Benzinga
News headline image
Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗
Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following... 
Via Talk Markets
Topics Stocks
News headline image
Option Volatility And Earnings Report For February 2 - 6
Last week we saw a plethora of important earnings results and increased market volatility. This wee should be another busy one with a lot of important companies due to report. 
Via Barchart.com
News headline image
3 Headwinds Facing Pfizer in 2026 ↗
Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Earnings To Watch: Pfizer (PFE) Reports Q4 Results Tomorrow
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market open. Here’s what investors should know. 
Via StockStory
News headline image
Here's Why Pfizer Stock Is Still a Buy ↗
Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting. 
Via The Motley Fool
Topics Intellectual Property
News headline image
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? ↗
Johnson & Johnson is a picture of stability. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗
All three can provide you with solid, consistent income. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.